PITTSBURGH, April 18, 2014 /PRNewswire/ -- Mylan Inc.
(Nasdaq: MYL) today announced that Supreme Court Chief Justice Roberts has denied Teva's application
for an injunction seeking to prevent Mylan's launch of a generic
version of Copaxone® pending the Supreme
Court's decision on Teva's appeal. This is the second time that the
Chief Justice has denied Teva's request for such an
injunction.
In March, the Supreme Court granted Teva's petition for
certiorari seeking clarification of the standard of review that
appellate courts should apply when considering appeals relating to
the construction of a patent claim. Oral argument is expected to be
heard in the fall of 2014.
Mylan CEO Heather Bresch
commented: "We are pleased with the Chief Justice's decision, and
we look forward to introducing the first generic
Copaxone® treatment for multiple sclerosis patients in
the U.S. at market formation. Mylan remains eligible to
receive approval from the U.S. Food and Drug Administration on
May 25, 2014."
This press release includes statements that constitute
"forward-looking statements," including with regard to litigation
and sales of products. These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Because such statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to: any legal or regulatory challenges to the
settlement; strategies by competitors or other third parties to
delay or prevent product introductions; risks inherent in legal and
regulatory processes; and the other risks detailed in the company's
filings with the Securities and Exchange Commission. The company
undertakes no obligation to update these statements for revisions
or changes after the date of this release.
Mylan is a global pharmaceutical company committed to setting
new standards in health care. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for
it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.